# name
The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to
                Evaluate the Potential of Ivermectin to Reduce COVID-19
                Transmission in low risk, non-severe COVID-19 patients in the
                first 48 hours after symptoms onset: A structured summary of a
                study protocol for a randomized control pilot trial

# metadata.dc.description.abstract[].value
Objectives: The primary objective is to determine the efficacy of a single dose of ivermectin, administered to low
risk, non-severe COVID-19 patients in the first 48 hours after symptom onset to reduce the proportion of patients
with detectable SARS-CoV-2 RNA by Polymerase Chain Reaction (PCR) test from nasopharyngeal swab at day 7
post-treatment.

# metadata.dc.source[].value
Articles publicats en revistes (ISGlobal)

# metadata.dc.title[].value
The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to
                Evaluate the Potential of Ivermectin to Reduce COVID-19
                Transmission in low risk, non-severe COVID-19 patients in the
                first 48 hours after symptoms onset: A structured summary of a
                study protocol for a randomized control pilot trial